Clinical trials in Charleroi

1 305 clinical trials in Charleroi, Belgium across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Charleroi at a glance

1 305

clinical trials

Research sites1

Quick filters

1 305 trials in Charleroi

Open in trial search

Cardiac failure

Recruiting

Study of maridebart cafraglutide for patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational

Study of maridebart cafraglutide for patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational

Belgium

Participants:18–64 years · 65+ years
Substances:Maridebart Cafraglutide
Sponsor:Amgen Inc.

Contact Research Centre

Sjogren's syndrome

Recruiting

Phase 3 Randomized, Double‑Blind Study of Telitacicept versus Placebo for Efficacy and Safety in Adults with Active Primary Sjögren’s Disease

Investigational

Phase 3 Randomized, Double‑Blind Study of Telitacicept versus Placebo for Efficacy and Safety in Adults with Active Primary Sjögren’s Disease

Investigational

Belgium

Participants:18–64 years · 65+ years
Substances:Telitacicept
Sponsor:Vor Biopharma Inc.

Contact Research Centre

Obesity+1

Recruiting

Phase 3 Extension Trial Evaluating Long‑Term Efficacy, Safety and Tolerability of maridebart cafraglutide in Adults with Obesity

Investigational

Phase 3 Extension Trial Evaluating Long‑Term Efficacy, Safety and Tolerability of maridebart cafraglutide in Adults with Obesity

Investigational

Belgium

Participants:18–64 years · 65+ years
Substances:Maridebart Cafraglutide
Sponsor:Amgen Inc.

Contact Research Centre

Sjogren's syndrome

Recruiting

Efficacy and safety of efgartigimod alfa in adults with Sjögren’s disease‑associated sensorimotor or sensory polyneuropathy: a phase 2 randomized placebo‑controlled study

Registered drug

Efficacy and safety of efgartigimod alfa in adults with Sjögren’s disease‑associated sensorimotor or sensory polyneuropathy: a phase 2 randomized placebo‑controlled study

Registered drug

Belgium

Participants:18–64 years · 65+ years
Substances:Efgartigimod Alfa
Sponsor:Argenx

Contact Research Centre

Graves' disease

Recruiting

Phase 3 Randomized Placebo‑Controlled Study of Efgartigimod Alfa in Adults with Graves’ Disease Inadequately Controlled by Antithyroid Drugs

Registered drug

Phase 3 Randomized Placebo‑Controlled Study of Efgartigimod Alfa in Adults with Graves’ Disease Inadequately Controlled by Antithyroid Drugs

Registered drug

Belgium

Participants:18–64 years · 65+ years
Substances:Efgartigimod Alfa
Sponsor:Argenx

Contact Research Centre

Asthma

Recruiting

Safety and Tolerability of Benralizumab in Patients with HES, EGPA, or Asthma Who Completed a Prior Study

Registered drugNo placebo

Safety and Tolerability of Benralizumab in Patients with HES, EGPA, or Asthma Who Completed a Prior Study

Registered drugNo placebo

Belgium

Participants:0–17 years · 18–64 years · 65+ years
Substances:Benralizumab
Sponsor:Astrazeneca AB

Contact Research Centre

Study of JNJ-78934804 (guselkumab and golimumab) versus guselkumab in adults with moderately to severely active Crohn’s disease

Recruiting

InvestigationalNo placebo

Study of JNJ-78934804 (guselkumab and golimumab) versus guselkumab in adults with moderately to severely active Crohn’s disease

InvestigationalNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Golimumab
Sponsor:Janssen Cilag International

Contact Research Centre

Narcolepsy

Recruiting

Efficacy and Safety of ALKS 2680 and Alixorexton in Adults with Narcolepsy Type 1

Investigational

Efficacy and Safety of ALKS 2680 and Alixorexton in Adults with Narcolepsy Type 1

Investigational

Belgium

Participants:18–64 years · 65+ years
Substances:ALKS 2680
Sponsor:Alkermes Inc.

Contact Research Centre

A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis

Recruiting

Investigational

A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis

Investigational

Belgium

Participants:18–64 years
Substances:Orelabrutinib
Sponsor:Zenas Biopharma (USA) LLC

Contact Research Centre

Metabolic dysfunction-associated steatohepatitis

Recruiting

A Phase 3 Study of Efimosfermin Alfa to Assess Safety and Tolerability in Adults with F2‑F3 Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational

A Phase 3 Study of Efimosfermin Alfa to Assess Safety and Tolerability in Adults with F2‑F3 Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational

Belgium

Participants:18–64 years · 65+ years
Substances:Efimosfermin alfa
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Small cell lung cancer

Recruiting

Phase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer

Registered drugNo placebo

Phase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:ZL-1310
Sponsor:Zai Lab (US) LLC

Contact Research Centre

Narcolepsy

Recruiting

Phase 3 Randomized, Double‑Blind, Placebo‑Controlled Study of ALKS 2680 for Excessive Daytime Sleepiness in Adults with Narcolepsy Type 2

Investigational

Phase 3 Randomized, Double‑Blind, Placebo‑Controlled Study of ALKS 2680 for Excessive Daytime Sleepiness in Adults with Narcolepsy Type 2

Investigational

Belgium

Participants:18–64 years · 65+ years
Substances:ALKS 2680
Sponsor:Alkermes Inc.

Contact Research Centre

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Charleroi

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on advanced cancer treatments, particularly in breast cancer, lung cancer, and head and neck cancers. Studies evaluate novel therapeutic approaches including immunotherapy combinations and targeted treatments.

HER2-positive breast cancer imaging studies
Non-small cell lung cancer therapies
Triple-negative breast cancer treatment

Multiple trials investigating personalized medicine approaches and biomarker-driven treatments.

02 Cardiovascular Studies

Research examining treatments for coronary artery disease and post-cardiac arrest care. Trials focus on innovative stent technologies and antiplatelet therapy optimization.

Antiplatelet therapy optimization
Post-cardiac arrest management
Novel stent technologies

Emphasis on improving patient outcomes through targeted interventional approaches.

03 Dermatology and Immunology

Clinical investigations targeting inflammatory skin conditions and immune-mediated disorders. Studies evaluate novel treatments for psoriasis and other dermatological conditions.

Plaque psoriasis treatments
Prurigo nodularis therapies
Severe asthma management

Focus on developing targeted therapies for chronic inflammatory conditions.

Back to Belgium All countries

Clinical trials in Charleroi

1 305 trials in Charleroi

Cardiac failure

Study of maridebart cafraglutide for patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Sjogren's syndrome

Phase 3 Randomized, Double‑Blind Study of Telitacicept versus Placebo for Efficacy and Safety in Adults with Active Primary Sjögren’s Disease

Obesity+1

Phase 3 Extension Trial Evaluating Long‑Term Efficacy, Safety and Tolerability of maridebart cafraglutide in Adults with Obesity

Sjogren's syndrome

Efficacy and safety of efgartigimod alfa in adults with Sjögren’s disease‑associated sensorimotor or sensory polyneuropathy: a phase 2 randomized placebo‑controlled study

Graves' disease

Phase 3 Randomized Placebo‑Controlled Study of Efgartigimod Alfa in Adults with Graves’ Disease Inadequately Controlled by Antithyroid Drugs

Asthma

Safety and Tolerability of Benralizumab in Patients with HES, EGPA, or Asthma Who Completed a Prior Study

Study of JNJ-78934804 (guselkumab and golimumab) versus guselkumab in adults with moderately to severely active Crohn’s disease

Study of JNJ-78934804 (guselkumab and golimumab) versus guselkumab in adults with moderately to severely active Crohn’s disease

Narcolepsy

Efficacy and Safety of ALKS 2680 and Alixorexton in Adults with Narcolepsy Type 1

A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis

A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis

Metabolic dysfunction-associated steatohepatitis

A Phase 3 Study of Efimosfermin Alfa to Assess Safety and Tolerability in Adults with F2‑F3 Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Small cell lung cancer

Phase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer

Narcolepsy

Phase 3 Randomized, Double‑Blind, Placebo‑Controlled Study of ALKS 2680 for Excessive Daytime Sleepiness in Adults with Narcolepsy Type 2

Filter the trials

Other cities in Belgium

Clinical research in Charleroi

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Clinical trials in Charleroi

1 305 trials in Charleroi

Obesity+1

Other cities in Belgium

Related

Clinical research in Charleroi

Prefer not to search on your own, or looking for clinical trials for a rare disease?